FDA Approves the Emergency Use of Johnson & Johnson’s Single-Dose COVID-19 vaccine

The Johnson & Johnson’s Single-Dose COVID-19 vaccine has been approved for emergency use. This FDA-approved vaccine seems to…
Johnson & Johnson's single-dose

The Johnson & Johnson’s Single-Dose COVID-19 vaccine has been approved for emergency use. This FDA-approved vaccine seems to be very effective, although it has its drawbacks.

There are now three different vaccines that have proved to be effective in preventing the spread of COVID-19. Only a few would have had this projection a year ago.

The novel coronavirus which has claimed the lives of about 2.5 million people is a major concern all over the world. This virus had a huge negative impact in most economies and the United States is one of the countries badly impacted.

According to a scholar with the Centre for Health Security in John Hopkins, this third vaccine is a huge achievement as more people still need to be vaccinated. The shipment of this vaccine will start soon after it was authorized. Many states are expected to start administering the vaccine as supply increases within weeks.

The company revealed that about 20 million doses of Johnson & Johnson’s single-dose COVID-19 vaccine will be supplied by March ending and about 100 million doses in the first half of 2021.

You can also read: Gary Sinise Has Launched a Mental Health Network For First Responders and Veterans

Only adults who are 18 years and above can take this vaccine. However, it has an advantage over the former two vaccines as it doesn’t need to be frozen and only requires to be administered once.

This vaccine is a better alternative for rural areas that are hard to locate. It also makes it easy to distribute to health centers and communities that have no freezers to preserve the other vaccines, according to public health officials.

Although the Johnson & Johnson’s vaccine seems to be perfect, it has its own drawbacks. Public health experts have expressed their worries about the low efficacy rate of this vaccine. This might make it seen as a low standard vaccine. In general, the efficacy rate of this vaccine is 66% and 72% in the US in preventing COVID-19.

Moderna, a vaccine produced by Pfizer and BioNTech is 95% potent after its two doses have been administered. The low efficacy rate of this new vaccine has instilled doubt in some people. However, the three vaccines have been reported to have a good efficacy rate and can help prevent the spread of coronavirus.

Featured image source

Total
0
Shares
Related Posts